Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Large Growth in Short Interest

Capricor Therapeutics Inc (NASDAQ:CAPR) was the target of a significant growth in short interest in November. As of November 30th, there was short interest totalling 4,410,000 shares, a growth of 14.5% from the November 15th total of 3,850,000 shares. Based on an average daily volume of 3,430,000 shares, the short-interest ratio is presently 1.3 days.

Capricor Therapeutics Stock Performance

Capricor Therapeutics stock traded up $0.77 during trading on Monday, reaching $14.03. 949,684 shares of the company’s stock were exchanged, compared to its average volume of 1,181,458. The firm has a market cap of $637.94 million, a price-to-earnings ratio of -13.58 and a beta of 3.98. Capricor Therapeutics has a 52-week low of $3.52 and a 52-week high of $23.40. The company’s 50-day moving average is $18.42 and its two-hundred day moving average is $10.07.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a report on Thursday, November 14th. Piper Sandler assumed coverage on Capricor Therapeutics in a research note on Monday, October 21st. They set an “overweight” rating and a $35.00 price objective for the company. Cantor Fitzgerald increased their price objective on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. Oppenheimer reissued an “outperform” rating and issued a $15.00 target price on shares of Capricor Therapeutics in a report on Monday, September 23rd. Finally, Maxim Group lifted their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $34.50.

Insiders Place Their Bets

In other news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the firm’s stock in a transaction on Friday, September 20th. The shares were bought at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the purchase, the insider now directly owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. This trade represents a 65.21 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 12.00% of the company’s stock.

Institutional Trading of Capricor Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CAPR. Main Street Financial Solutions LLC lifted its position in Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 7,500 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Capricor Therapeutics during the third quarter valued at approximately $133,000. Bank of New York Mellon Corp boosted its position in shares of Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after buying an additional 9,040 shares during the period. The Manufacturers Life Insurance Company bought a new position in Capricor Therapeutics in the 3rd quarter worth approximately $161,000. Finally, Sassicaia Capital Advisers LLC bought a new stake in Capricor Therapeutics during the 3rd quarter valued at $192,000. 21.68% of the stock is owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.